Monday, August 20, 2018
 
 
Company News: Page (1) of 1 - 02/14/18 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
Biofrontera AG (Nasdaq: BFRA) to Ring The Nasdaq Stock Market Closing Bell

(February 14, 2018)

ADVISORY, Feb. 14, 2018 (GLOBE NEWSWIRE) --

What: 

Biofrontera AG (Nasdaq:BFRA), the specialist for the treatment of sun-induced skin cancer, will visit the Nasdaq MarketSite in Times Square.

In honor of the occasion, Prof. Hermann Lübbert, PhD, Chief Executive Officer, will ring the Closing Bell. 

Where:Nasdaq MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio

When:


Thursday, February 15, 2018 – 3:45 p.m. to 4:00 p.m. ET

Biofrontera Contact:
Joanna Zimmerman
(646) 536-7006
[email protected] 

Nasdaq MarketSite Media Contact:
Emily Pan
(646) 441-5120
[email protected]

Feed Information:
Fiber Line (Encompass Waterfront): 4463

Gal 3C/06C 95.05 degrees West
18 mhz Lower
DL 3811 Vertical
FEC 3/4
SR 13.235
DR 18.295411
MOD 4:2:0
DVBS QPSK

Social Media:
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies, please visit our Facebook page:
http://www.facebook.com/NASDAQ.

For photos from ceremonies and events, please visit our Instagram page:
http://instagram.com/nasdaq

For livestream of ceremonies and events, please visit our YouTube page:
http://www.youtube.com/nasdaq/live

For news tweets, please visit our Twitter page:
http://twitter.com/nasdaq

For exciting viral content and ceremony photos, please visit our Tumblr page:
http://nasdaq.tumblr.com/

Webcast:
A live stream of the Nasdaq Closing Bell will be available at:
https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx

Photos:
To obtain a hi-resolution photograph of the Market Close, please go to http://business.nasdaq.com/discover/market-bell-ceremonies and click on the market close of your choice.

About Biofrontera AG
Biofrontera AG is an international biopharmaceutical company specializing in the development and commercialization of a platform of pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that results in sun damage to the skin. Biofrontera’s approved products focus on the treatment in the U.S. and Europe of actinic keratoses, which are skin lesions that can sometimes lead to skin cancer, as well as the treatment of certain forms of basal cell carcinoma in the European Union. American Depositary Shares representing Biofrontera’s ordinary shares will commence trading on the NASDAQ Capital Market under the symbol “BFRA” on February 14, 2018, and Biofrontera’s ordinary shares are listed in the Frankfurt Stock Exchange (B8F, ISIN: DE0006046113). Information is also available at www.biofrontera.com.

About Nasdaq:
Nasdaq (Nasdaq:NDAQ) is a leading global provider of trading, clearing, exchange technology, listing, information and public company services. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 90 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to approximately 3,900 total listings with a market value of approximately $13 trillion. To learn more, visit: http://business.nasdaq.com  

-NDAQA-


Page: 1


Related Keywords:
Related Sites: IBN - Business ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter
 
 
 
 
 
 
 
Seniors

Drugs
  • Neurovascular Devices Market High Revenue at USD 24,650 mn by 2023 | Therapeutic Application Hemorrhagic & Ischemic Strokes | Worldwide Segmentation by MRFR
  • The global connected health device market is expected to reach an estimated $36.1 billion by 2023 and is forecast to grow at a CAGR of 21.1% from 2018 to 2023
  • Global Hemodialysis and Peritoneal Dialysis Market to Witness a CAGR of 5.9% during 2018-2024
  • The Alzheimer's Research and Prevention Foundation (ARPF) Announces Second Brain Longevity® Therapy Training Program in Washington D.C.
  • Image Guided Radiotherapy Market to Experience Unfaltering Growth at 15.8% CAGR to Revolutionize the Healthcare Sector by 2023

    Cancer
  • Information Update - Teva Canada expands recall of valsartan drugs to include additional lots, as a precaution
  • /R E P E A T -- Information Update - Teva Canada expands recall of valsartan drugs to include additional lots, as a precaution/
  • Singapore's first clinical trial approval for T cell engineered (TCR) immunotherapy for treatment of Liver cancer
  • ViewRay Announces Full Exercise of Underwriters' Option to Purchase Additional Shares and Closing of Public Offering of Common Stock
  • Mirati Therapeutics Announces Presentation Of KRAS G12C Chemistry Advances At The 255th American Chemical Society (ACS) National Meeting And Exposition
  •  
     
     
     
     
     





    Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines